Capricor Therapeutics, Inc. (CAPR)
| Market Cap | 580.10M |
| Revenue (ttm) | 22.27M |
| Net Income (ttm) | -40.47M |
| Shares Out | 45.68M |
| EPS (ttm) | -1.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 562,584 |
| Open | 12.17 |
| Previous Close | 12.56 |
| Day's Range | 12.16 - 12.87 |
| 52-Week Range | 3.52 - 23.40 |
| Beta | 4.67 |
| Analysts | Strong Buy |
| Price Target | 39.29 (+209.37%) |
| Earnings Date | May 12, 2025 |
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and... [Read more]
Financial Performance
In 2024, Capricor Therapeutics's revenue was $22.27 million, a decrease of -11.55% compared to the previous year's $25.18 million. Losses were -$40.47 million, 81.6% more than in 2023.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CAPR stock is "Strong Buy." The 12-month stock price forecast is $39.29, which is an increase of 209.37% from the latest price.
News
Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marban - Chief Executive Office...
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise...
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
--Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data Presented at the 2025 Muscular Dystrophy Association (MDA) Conference--
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
PARAMUS, N.J. , March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd.
Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise...
Capricor: Further Value Unlocked With Priority Review Of Deramiocel
Capricor Therapeutics, Inc.'s Deramiocel received FDA Priority Review with a PDUFA target date of August 31, 2025, for the treatment of patients with DMD Cardiomyopathy. Deramiocel could become the fi...
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition
On Tuesday, the FDA accepted for review Capricor Therapeutics Inc's CAPR Biologics License Application for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duche...
Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data
Capricor Therapeutics has filed a BLA for deramiocel, showing promising results in slowing cardiac dysfunction in DMD cardiomyopathy, with strong FDA recognition. Deramiocel's efficacy was demonstrate...
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku- SAN DI...
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thu...
Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached
Capricor Therapeutics is advancing deramiocel, an allogeneic cell therapy for DMD-related cardiomyopathy, with a rolling BLA submission and potential FDA approval by 2025. Deramiocel showed significan...
Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission
Capricor Therapeutics initiated its rolling BLA submission for Deramiocel to treat Duchenne Muscular Dystrophy Cardiomyopathy, with completion expected before the end of 2024. The company presented pr...
Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Off...
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...
Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
-Data Supports Deramiocel's Sustained Efficacy and Safety in Treating DMD- -Improvements Seen in Multiple Cardiac and Skeletal Endpoints Demonstrating Stabilization of Cardiac and Skeletal Muscle Func...
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA-
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more t...
Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off
BLA submission of deramiocel for treatment of patients with DMD cardiomyopathy is expected in October 2024, with the completed portion expected before the end of 2024. The Duchenne Muscular Dystrophy ...
Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise...
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Million in Potential Milestones and a Doub...